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In vivo DDAVP selectively and markedly enhances the ability to form procoagulant platelets, by enhancing intracellular Na + and Ca 2+ fluxes.
For personal use only. on July 16, 2017 . by guest www.bloodjournal.org From Introduction 1-deamino-8-D-arginine vasopressin (DDAVP, desmopressin), a synthetic analogue of the natural antidiuretic hormone L-arginine vasopressin (AVP), was originally employed for treating diabetes insipidus and enuresis. 1 The favourable pharmacodynamic profile of DDAVP compared to AVP and other mimetic synthetic compounds derives from its minimal effect on V1 vasopressin receptors (mediating vasoconstriction) and almost selective antidiuretic action, mediated by V2 receptors. 1 In a seminal publication 1977 Mannucci et al. 2 showed that DDAVP can prevent bleeding during dental extraction and major surgery in patients with mild haemophilia
A or von Willebrand disease (VWD). This haemostatic effect of DDAVP is mediated via activation of V2 vasopressin receptors on endothelial cells and intracellular cAMP-dependent signalling leading to exocytosis of von Willebrand factor (VWF) and
tissue plasminogen activator (t-PA) from Weibel-Palade bodies. 3 The rise in factor VIII activity (FVIII:C) is thought to be secondary to the rise of its carrier protein, VWF. 3 Subsequently, it has been observed that DDAVP is clinically efficacious in patients with various, generally mild disorders of the platelet function as well [4] [5] [6] [7] [8] [9] and, although data are still limited almost exclusively to case reports, its use is recommended for bleeding prophylaxis in patients at low personal bleeding risk. 9, 10 An enhanced hemostasis in patients with disorders of the platelet function might be mediated by the DDAVP-induced rise of circulating VWF high molecular weight multimers, leading to an increased platelet adhesion to the injured vessel wall; however, although this mechanism is biologically plausible it has not yet been proven. 11 On the other hand, the documented efficacy of DDAVP in patients with type 3 VWD (lacking VWF in
For personal use only. on July 16, 2017 . by guest www.bloodjournal.org From 5 endothelial stores) 12, 13 and in patients with Bernard Soulier syndrome (lacking glycoprotein Ib, the platelet receptor for VWF) 14, 15 clearly indicates that additional mechanisms are responsible for the in vivo haemostatic effects of DDAVP as well. In this regard, the lack of efficacy in patients with Glanzmann thrombasthenia [16] [17] [18] indicates that DDAVP cannot substitute for a missing or severely dysfunctional fibrinogen receptor. Several hypothetical mechanisms have been proposed for explaining the clinical benefit of DDAVP in patients with platelet disorders, but their physiological role is uncertain. 9, 11 The aim of the present work was to investigate the effect of in vivo DDAVP administration on platelet adhesive and procoagulant functions. In particular, we have also investigated the impact of DDAVP on the generation of COAT platelets. This is a subpopulation of highly procoagulant platelets induced by combined activation with collagen and thrombin, and characterized by the expression of negatively charged aminophospholipids, surface retention of α -granule proteins (such as factor V/Va and VWF) and preferential binding of factor Xa, 19, 20 whose potential clinical relevance is increasingly recognized.
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Materials and Methods

Patients
We enrolled patients diagnosed with mild congenital platelet function defects at our institution receiving as a part of routine work-up an elective test dose of DDAVP. A diagnosis of primary platelet function disorder was made if the patient had not taken any drugs known to affect platelet function for at least 10 days before investigation, had normal platelet counts, an abnormal (but not absent) platelet aggregation to standard platelet agonists (ADP, arachidonic acid, collagen), an abnormal (but not absent) agglutination to ristocetin, and a positive bleeding history.
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Platelet aggregation abnormalities had to be confirmed in a blood sample drawn at a later time point.
Overall, we investigated 93 patients (69 women) with a median age of 42 years (interquartile range 27 -52 years, range 18 -77 years). The observed platelet aggregation defects were as follows: 38 patients had an impaired response to a single agonist (ADP n=32, collagen n=4, arachidonic acid n=1, ristocetin n=1), 28 patients had an impaired response to two agonists (ADP and collagen n=25, collagen and arachidonic acid n=3), 24 patients had an impaired response to three agonists (ADP, collagen and arachidonic acid), and 3 patients had an impaired response to all four investigated agonists. Because of their rarity, we did not include patients with Glanzmann thrombasthenia and Bernard-Soulier syndrome. The study was approved by the deputy ethical board and patients gave informed written consent. The study was conducted in accordance with the Declaration of Helsinki. 
Blood sampling and coagulation assays
Whole blood samples were obtained before, 2 and 4 hours after DDAVP-infusion with a 19-gauge needle from the antecubital vein into three 10 ml plastic tubes each containing 1 ml 0.13 M trisodium citrate pH 5.5 for platelet aggregation studies, two 3.8 ml plastic syringes (Monovette, Sarstedt, Nümbrecht, Germany) containing 0.38 ml 0.129 M buffered citrate pH 5.5 for platelet function analyser (PFA) studies, and two 10 ml plastic syringes (Monovette, Sarstedt, Nümbrecht, Germany) containing 1 ml of 0.106 M trisodium citrate for flow cytometric and coagulation studies.
Analysis of coagulation parameters
Coagulation assays and VWF analysis were performed as described.
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Platelet function analyzer (PFA)
The PFA (PFA-100® and INNOVANCE® PFA-200™ System, Siemens Healthcare Diagnostics, Germany) is a tool for investigating von Willebrand factor and platelet function.
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Light transmission platelet aggregation tests (LTA) in platelet rich plasma (PRP)
LTA testing was performed as already described. 25 Specifically, venous blood samples were collected into buffered 0.13 M trisodium citrate (9:1 blood-to-citrate ratio), transported to the laboratory at room temperature (RT) and processed immediately. PRP was prepared by centrifugation at 150g for 15 minutes at RT. The LTA started 1 hour after blood collection and was completed within 2.5 hours.
Flow cytometric analysis of platelet function
PRP from the patient and a normal donor was diluted to 10 x10 6 platelets/ml with 
Thrombin generation.
Thrombin generation (TG) in platelet-rich plasma (PRP) was measured by calibrated automated thrombography (CAT) with commercial reagents as published by Hemker et al. 27 In order to exclude the effect of plasmatic factors and therefore exclusively We employed an in-house modification of the method described by Monteiro et al. Software Inc., San Jose, CA, USA). Significance was set at the 5% level.
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Results
The effect of in vivo DDAVP on VWF, FVIII:C, and in vitro bleeding time
The efficacy of DDAVP (0.3 μ g/kg body weight) was documented in all 93 patients by its ability to induce an increase in VWF and FVIII:C, and a shortening of the in vitro bleeding times assessed by PFA-system ( Figure 1 ).
The effect of in vivo DDAVP on platelet aggregation
In order to evaluate whether infusion of DDAVP would also have a direct impact on platelet function we first tested platelet aggregation in platelet-rich-plasma (PRP) from 10 patients (6 women, median age 44 years, range 16 -60 years) 4 hours after DDAVP. We assessed platelet aggregation 3 minutes after addition of increasing concentrations of ADP, collagen, arachidonic acid, and ristocetin. In addition we also recorded the time delay between agonist's addition and onset of the aggregation curve (lag phase) for collagen and arachidonic acid. At baseline, 4 patients had a blunted aggregation in response to a single agonist (ADP n=3, collagen n=1), one had a blunted aggregation in response to ADP and collagen, and 5 had a blunted aggregation in response to ADP, collagen and arachidonic acid. Table 1 and Figure   2 demonstrate that we did not observe any significant change between baseline and platelets drawn 4 hours after start of the DDAVP infusion.
The effect of in vivo DDAVP on surface expression of GPIb and GPIIb-IIIa
Subsequently, we investigated platelets by flow cytometry, comparing several phenotypic and functional characteristics before, 2 and 4 hours after DDAVP (n=16).
Since we did not observe any significant difference at 2 versus 4 hours we pooled the data for these two time points. We observed a slight, statistically significant decrease of the fibrinogen receptor (Fig. 3A) : GPIIb decreased by 10.6% (95% C.I.: -12.3 --For personal use only. on July 16, 2017. by guest www.bloodjournal.org From 13 1.3; p=0.006, Wilcoxon signed rank test; n=16) and GPIIIa decreased by 4.3% (95% C.I.: -9.9 --0.5; p=0.044). We did not find a statistically significant change in GPIb surface expression, which showed a median decrease of -3.5% (95% C.I.: -8.2 -3.3; p=0.323). 
The effect of in vivo DDAVP on platelet dense granule
The effect of in vivo DDAVP on COAT platelet generation
COAT platelets were induced by simultaneous activation with convulxin (500 ng/ml) and thrombin (5 nM). at baseline; 1.2% 2 hours and 1.4% 4 hours after DDAVP; p=0.052).
The effect of in vivo DDAVP on thrombin generation
Thrombin generation (TG) induced by simultaneous platelet activation with convulxin and thrombin was measured by CAT 27 in platelet-rich plasma (PRP) and in gel- 
Intracellular free Ca 2+ changes and COAT platelet generation after DDAVP
In order to explore the mechanisms involved in the formation of procoagulant COAT platelets we studied intracellular free Ca 2+ flux. Figures 6A and 6B show the rapid and sustained increase of intracellular Ca 2+ observed in native platelets up to 6 minutes after simultaneous activation with convulxin and thrombin. Among patients in whom DDAVP induced a significant increase of COAT platelet generation we observed an enhanced ability to mobilize Ca 2+ after DDAVP compared to baseline ( Figures 6C and 6D ). On the other hand, in patients among whom COAT platelets remained unchanged, Ca 2+ mobilization after DDAVP was lower than at baseline ( Figure 6D ).
For
Intracellular Na + changes and COAT platelet generation after DDAVP
Similar experiments performed with CoroNa green showed a slower and less marked increase of cytosolic Na + , peaking at 2 to 4 minutes after activation with convulxin and thrombin ( Figure 7A and 7B ). This transient intracellular Na + increase was enhanced by DDAVP among individuals reacting with an increased COAT platelet generation, while remained unchanged in those patients whose COAT platelet generation was unaffected by DDAVP ( Figure 7C ).
Discussion
We investigated the effect of an in vivo DDAVP infusion, at a standard dose of 0. We investigated platelet aggregation 4 hours after DDAVP infusion and from this perspective the data from both publications are congruent.
Noteworthy, the effect of DDAVP on VWF appears to have a similar time-dependent course ( Figure 1) and it may be possible that an early, transient enhancement in The most interesting observation of our study is the ability of in vivo DDAVP infusion
to enhance the generation of procoagulant COAT platelets (Figures 4). COAT
For personal use only. on July 16, 2017. by guest www.bloodjournal.org From platelets are a subpopulation of platelets generated by simultaneous activation with collagen and thrombin. 19 Only these activated platelets express negatively charged phospholipids and high levels of α-granule factor V/Va on their surface, are able to bind exogenous factor Xa, and are most efficient in sustaining thrombin generation. 19, 21 We named this subset of COllagen And Thrombin activated platelets as "COAT platelets" in order to convey the concept of their surface being covered by a layer, a coat of adhesive and procoagulant proteins.
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In the present work we show a progressive increase in COAT platelets 2 and 4 hours after DDAVP infusion ( Figure 4B ). Since COAT platelets are procoagulant we also investigated their functional relevance by assessing the ability to sustain thrombin generation. As expected and already published by Keularts et al. 29 DDAVP infusion improves, by means of increased VWF-levels, thrombin generation in PRP ( Figure 5 and Online Supplemental Material). We therefore modified the CAT assay in order to specifically assess platelet-dependent thrombin-generation (see Methods Section).
As depicted in Figure 5 , after DDAVP we observe a significant rise in platelet ability to sustain thrombin generation, paralleling the increased percentage of COAT platelets and documenting their functional relevance. 
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Several proteins become phosphorylated upon DDAVP action 45, 46 and some of them are involved in Na + retention. 47, 48 Of note, an increase in intracellular Na + has been shown to promote an increase of intracellular Ca 2+ 49,50 and could thus facilitate an agonistinduced, high and prolonged rise in intracellular Ca 2+ required for the exposure of negatively charged aminophospholipids on the platelet surface. 51 55 Among our patients we observed a slight, statistically significat decrease of the MPV 4 hours after DDAVP (7.9 fl at baseline, 7.9 fl 2 hours, and 7.7 fl 4 hours after DDAVP; p=0.045, n=93). This could be explained by the fact that after an in vivo infusion (0.3 µg/kg b.w.) the expected pharmacological DDAVP concentration is around 1-5 nM, 18 much lower than the concentrations tested by Tomasiak et al. 55 We are not aware of publications evaluating the impact of DDAVP on other platelet Na + channels. However, the transient nature of the observed Na + increase (Figures 7 A-B) suggests a role for the Na + /Ca 2+ exchanger. 52, 53 In conclusion, this is the first report showing that in vivo administration of DDAVP selectively and markedly enhances the ability to form procoagulant COAT platelets and increases platelet-dependent thrombin-generation up to 4 hours after infusion.
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